Medical Microinstruments Secures Series D Funding
Medical Microinstruments, Inc., a robotics company focused on enhancing treatment options and improving patient outcomes for complex medical conditions, has announced the successful raising of $125 million in a Series D funding round. The round was led by BioStar Capital, with additional investments from S3 Ventures and Angelini Ventures. This latest financial boost is aimed at furthering the company’s commercial growth and expanding the reach of its Symani Surgical System.
Investment Details
The Series D round marks a significant step in Medical Microinstruments' growth strategy. With BioStar Capital at the helm, the funding also attracted new investors, including S3 Ventures and Angelini Ventures, alongside participation from existing stakeholders. The influx of capital is set to bolster the company’s presence in the United States as well as key international markets.
Strategic Use of Funds
The funds raised will primarily be used to support the commercial expansion of the Symani Surgical System, which is designed to perform complex microsurgical procedures with precision. The company plans to enhance market accessibility and conduct further clinical trials to support the system's broader adoption. CEO Mark Toland commented, "We’ve proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale."
Expansion Plans
Currently, Medical Microinstruments has approximately 50 installed systems worldwide and has facilitated around 3,500 complex microsurgical procedures. The company aims to increase these numbers significantly, leveraging the new funding to strengthen its commercial operations and clinical evidence base. This includes investment in the REMIND study to further validate the system’s applications.
Conclusion
With this substantial Series D funding, Medical Microinstruments is well-positioned to accelerate its growth and reinforce its market position in robotic microsurgery. The company's ongoing commitment to expanding patient access and improving clinical outcomes continues to drive its strategic initiatives in the medical technology sector.